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Mechanism of Toxicity of Nitro Compounds
Used in the Chemotherapy of
Trichomoniasis
by Silvia N. J. Moreno* and Roberto Docampo*
The mechanism of the trichomonicidal activity of metronidazole and other 5-nitroimidazoles appears
to depend on the ferredoxin-mediated reduction of their nitro group, with generation of a reactive me-
tabolite or metabolites which interact with DNA leading to a subsequent inhibition of nucleic acid and
proteinsynthesis. Redoxcyclingofthesecompoundsunderaerobicconditions appearstobe adetoxification
reaction by inhibiting net reduction of the drugs, thereby inhibiting their uptake. On the other hand,
redoxcyclingofnitrofurans orothercompoundswith morepositivereductionpotential results information
of high steady-state concentrations of oxygen-derived metabolites that might be of toxicological signifi-
cance. It seems likely that reduced metabolites of nitroimidazoles (perhaps through covalent binding to
tissue macromolecules and/or thiols depletion) are also involved in the nitroimidazoles' toxic effects to
animal tissues and in their mutagenic and carcinogenic action.
Introduction
Human trichomoniasis, a chronic disease of the uro-
genital tract, is the most widespread of the sexually
transmitted diseases (1). This disease is estimated to
occur in about 20% ofthe female population ofthe U.S.
(2). In fact, the Centers for Disease Control estimate
that there are three million new cases oftrichomoniasis
each year, thereby surpassing the incidence ofsyphilis,
gonorrhea, and genital herpes combined (3). Tricho-
moniasis is caused by Trichomonas vaginalis, a pro-
tozoan parasite ofthe vagina or the male urethra. Clin-
ical manifestations of the disease vary even wong
patients of the same sex, since different strains of T.
vaginalis seem to have different pathogenic capabilties
(1). Symptoms may even worsen and improve repeat-
edly in the same patient. Consequently, while tricho-
moniasis in womenisusuallycharacterizedby acopious,
foamy, yellowish-green discharge that may have a foul
odor, as well as mild to severe vaginalitchingand burn-
ing, 25% of women harboring trichomonads have no
symptoms at all (1,4). Although early studies associated
trichomoniasis with cervical cancer (5), later studies
have failed to confirm such a link (6). However, the
prevalence of trichomoniasis is higher in women with
cervical cancer than in healthy women (7). While tri-
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chomoniasis in men is most often asymptomatic, it may
sometimes cause a slight urethral discharge which may
or may not be accompanied by irritation, and in some
cases it causes urethritis, prostatitis, epididymitis, and
constriction ofthe urethra (7).
Trichomonas vaginalis isusuallytransmitted by sex-
ual intercourse. However, it is generally acknowledged
that in unusual circumstances the disease may be con-
tracted through nonvenereal means (7), for example,
from communal bathing water, contact with contami-
nated bath or toilet articles, and possibly even contact
with urine on toilet seats (8). Infected women may also
transmit trichomoniasis to their infant children during
childbirth (7), and it has been suggested (9) that T.
vaginalis may cause neonatal pneumonia.
Although other species appear to be potential path-
ogens, the onesofmajorimportance inanimalpathology
are Tritrichomonas foetus in cattle and Trichomonas
gallinae and Trichomonas gallinarum in birds (10).
T. foetus is transmitted as a true venereal infection
in cattle. The disease may rarely be spread in other
ways (10). The affected cow may show some evidence
of vaginitis shortly after infection occurs, but usually
this is overlooked. The affictionbegins inthe vaginaand
soon invades the uterus. As a result ofthis, the animal
may fail to conceive. If conception occurs, the animal
may abort within 2 to 4 months as a result of the in-
fection. In other instances the fetus dies but is not dis-
charged, in which case it becomes macerated and liesMORENO AND DOCAMPO
in a thin, nearly odorless fluid in which many tricho-
monads may often be found (10). Some authors have
reported abortions ofpregnant guinea pigs and rabbits
by injection of T. foetus into the uterus (11). Artificial
insemination and chemotherapy have reduced the im-
portance of this disease in the U.S. but it is still of
importance in other countries.
T gallinae cause a disease affecting the upper diges-
tive tract ofpigeons, turkeys, chickens, and other birds
(10), while T gallinarum produces cecal and liver le-
sions in turkeys and chickens (10). Both these diseases
are widely distributed and can cause severe losses.
Sincetheearly 1960s different5-nitroimidazoles were
introduced for the treatment of trichomoniasis. Me-
tronidazole is the only member of the group available
for human use in the U.S. (1). Dimetridazole, iproni-
dazole, and ronidazole are used to prevent infections in
livestock (12), and tinidazole, nimorazole, carnidazole,
ornidazole, and secnidazole are used in other countries
as alternatives to metronidazole in the treatment ofhu-
man trichomoniasis (12-14). In addition, several nitro-
furans have been used for the treatment ofhuman and
animal trichomoniasis (13,15-17).
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human trichomoniasis, although none were particularly
effective (1,30). The antitrichomonad activity of me-
tronidazole [(1-(2-hydroxyethyl)-2-methyl-5-nitroimi-
dazole)] was reported in 1959 (31), and it was quickly
recognized that this compound is active against a wide
variety of anaerobic eukaryotic and prokaryotic micro-
organisms (20). Clinical use of metronidazole in the
treatment of human trichomoniasis began in 1960 in
Europe and in 1963 in the U.S. (32). During the more
than 20 years since the discovery of metronidazole, a
number of other useful nitroimidazoles have emerged.
This group ofcompounds, which includes tinidazole, or-
nidazole, nimorazole, carnidazole, and secnidazole, is
also clinically available for the treatment oftrichomon-
iasis in different countries but shows no sufficiently im-
proved activity overmetronidazole forthis disease (19).
Certainnitrofuranssuchasnifuratel, nitrofurazone, and
nitrofurantoin, active both in vitro and in vivo against
trichomonads, have also been used in the treatment of
human and cattle trichomoniasis (13,15-17,33), al-
though its use in human trichomoniasis has been dis-
continued.
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This review will focus only on the mechanism oftox-
icityofthenitrocompounds currentlyusedforthetreat-
ment of human and animal trichomoniasis. The litera-
ture on several nitroimidazoles and nitrofurans which
have been used against trichomoniasis has been ably
reviewed overtheyearsbyseveralauthors (18-29). We
have tried to minimize overlap with earlier reviews and
put the emphasis on the most recent work.
Drugs Used in the Chemotherapy of
Trichomoniasis
Until the late-1950s there was no successful, specific
treatment for trichomoniasis (30). Nearly 150 different
substances were then being used and recommended for
NITROFURAZONE
There is no doubt that nitroimidazoles are effective
in combating trichomoniasis. Thus, cure rates of 95%
or better can be expected from regimes of 200 mg of
metronidazole given orally three times a day for seven
days, or after a single oral dose of 2 g in humans (34).
Nitroimidazoles arealsoeffective againstotherdiseases
causedbyotherspecies ofprotozoans, such as amebiasis
(caused by Entamoeba histolytica), and giardiasis
(caused by Giardia lamblia). In addition, they are also
effective against various anaerobic infections caused by
a variety ofanaerobic bacteria such as Bacteroidesfra-
gilis, Clostridia, Peptoestreptococci, Fusobacteria, and
many others (34). They are commonly used to reduce
the risks of infection by anaerobic organisms after co-
lonic surgery(34). Finally, theabilityofseveralnitroim-
idazoles to enhance the response ofhypoxic cells to ra-
diation (35,36) or cytotoxic agents (37) has attracted
considerable interest in recent years.
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Free-Radical Intermediates in the
Toxicity of Nitro Compounds
The antiparasitic and genotoxic action of nitro com-
pounds is generally agreed to require the enzymatic
reduction ofthe nitro group, yielding a reactive metab-
olite. The complete reduction of the nitro group to an
amino group requires six electrons per molecule. The-
oretically, thereductioncanoccurinone-electron steps.
The complete reduction scheme, including both dia-
magnetic and free radical intermediates, is shown in
Eq. (1):
R-N02 e R-NO R-NO H
(Nitro) (Nitro anion (Nitroso) (Hydronitroxide
radical) radical)
e ~ e-
R-NHOH 2H R - H2 -, R-NH2
(Hydroxylamine) (Amino cation
radical)
(Amine)
There are three potential free-radical intermediates of
enzymaticnitroreduction: thenitro anion(R-NO2-), the
hydronitroxide (R-HNO ), and the amino cation free
radical (R-NH2+). Electron spin resonance studieshave
demonstrated the formation ofthe nitro anion free rad-
ical intermediate in the reduction of nitro compounds
by the oxygen-sensitive nitroreductases, which do not
form diamagnetic products in the presence of air (26).
No evidence is available so far on the formation ofthe
hydronitroxide and the amino cation free radicals in
nitroreductase incubations (26). Three chemical reac-
tions ofnitro free radicals could be ofimportance in the
toxicityofthesecompounds (26). Thefirstisthereaction
ofthe free radical with itself, i.e., disproportionation:
2H++ R-440 R-11O
--+
R-NO R-NO2 H20
This reaction might be either a detoxification reaction,
because the free radical destroys itself, or the pathway
to a more toxic species, such as the nitroso derivative
(26).
A second, possibly important reaction is the covalent
binding ofthe free radical metabolite to tissue macrom-
olecules. However, recent experiments have demon-
strated the unreactivity to DNA, proteins, or thiols of
the nitro anion radical derived from several nitro com-
pounds (26,38).
The third reaction, air oxidation of nitro anion free
radicals is the dominant pathway in the presence of 02
(26,39). Thisreactionresults inregeneration ofthenitro
compound and production of62- (39), whose dismuta-
tion yields H202 (40):
R-N02 H202
Reductose SOD
R-NO2 02 °2 + 2H+
Again, this reaction might be either a detoxification
reaction, because the free radical is oxidized and there
is no net reduction ofthe nitro compound, or the path-
waytomoretoxicspecies, suchasoxygen-reduction by-
products (02-, H202, OH-).
Analternative routefortheradicalanionhasrecently
been proposed based on results obtained after UV and
gamma-irradiation (41), and electrolysis (41,42) of me-
tronidazole in aqueous media:
R-NO2 -- R- + NO2 (4)
This reaction involves the formation of nitrite ion
(NO2 ), and ofa carbon-centered free radical (R-). Al-
thoughnitriteionhasbeendetectedintheseincubations
(41,42), no evidence is available so far on the formation
of a carbon-centered free radical upon nitroreduction.
Whether the radical intermediates, the diamagnetic
products ofnitroreduction, orthe oxygen-reduction by-
products generated by the autoxidation ofthe nitro an-
ion radical are involved in the antiparasitic and geno-
toxic action of nitro compounds will depend on several
factors, i.e., nitro compound, presence of appropriate
nitroreductases, presence of defense mechanisms
against the oxygen-reduction products, aerobic or an-
aerobic habitat of the cell, etc. The work of the past
few years has provided considerable insight into the
mechanisms by which some of these nitro compounds
exert their actions.
Mechanism of the Trichomonicidal
Action of Metronidazole and Other
Nitro Compounds
Theanaerobic incubation ofmetronidazole withintact
Ttririchomonas foetus (43) or Trichomonas vaginalis
(44) cells in the presence ofglucose determines the ap-
pearance ofa characteristic ESR spectrum correspond-
ingtothenitroanionradical. Thesignalisalsoobserved
in the absence ofadded glucose, indicating that endog-
enous reducing substrates can be used by the cells for
metronidazole reduction (43). However, the steady-
state concentration ofthe nitro anion radical is 40-50%
higher with added glucose. Pyruvate is the most effec-
tive exogenous substrate for metronidazole reduction
in incubations with T. foetus intact cells or homoge-
nates. Inaddition, reducedpyridine nucleotides canalso
be used formetronidazole anion radical formation by T.
foetus homogenates (43).
The ability of intact T. foetus to reduce nitro com-
pounds is not limited to metronidazole. Incubation of
several nitrofurans (nifuroxime, nifurtimox, nitrofur-
antoin) (45), 2-nitroimidazoles (benznidazole, misoni-
dazole) (43), and 5-nitroimidazoles [ronidazole, secni-
dazole (43), MK-436, fexinidazole (unpublished results)]
withintact T.foetusalsogeneratesmulti-lineESRspec-
tra corresponding to their respective nitro anion radi-
cals.
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The effectiveness of pyruvate as electron donor for
metronidazole reduction indicates the participation of
the pyruvate:ferredoxin oxidoreductase-catalyzed re-
action in this process. This reaction involves an oxida-
tive decarboxylation ofpyruvate in which the acceptor
for the reducing equivalents is a ferredoxin (46). This
ferredoxin is the natural electron carrier linking pyru-
vate oxidation [reaction (5) catalyzed by the pyru-
FIGURE 1. Electron micrographs ofTritrichomonasfoetu8: (A) Ultrathin section stained with uranyl acetate and lead citrate: BB, basalbody;
C, costa; H, hydrogenosome; N, nucleus; RF, recurrent flagellum. The arrow indicates the lateral arcuate system which surrounds the
costa. x 14,000. Bar = 1 ,um. From Benchimol et al. (47) with permission. (B) Cell fixed according co the glutaraldehyde-osmium tetroxide-
potassium ferrocyanide procedure (48). The two closely apposed outer (0) and inner (I) unit membranes of the hydrogenosome (H) are
clearly seen. x 66,000. Courtesy of Dr. Wanderley De Souza.
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vate:ferredoxin oxidoreductase] to H2 formation [reac-
tion (6), catalyzed by the hydrogenase]:
Pyruvate + CoA + 2 Fd --
acetyl-CoA + CO2 + 2 Fd- + 2H+ (5)
2Fd- + 2H-+2Fd +H2 (6)
Both these reactions occur in trichomonad hydrogeno-
somes, microbody-like organelles typical of these or-
ganisms(46)whicharedevoid ofothertypicaleukariotic
organelles such as mitochondria or peroxisomes (Fig.
1). Accordingly, the anaerobic incubation of metroni-
dazole with the T. foetus hydrogenosomal fraction in
the presence of pyruvate and CoA generates the me-
tronidazole anion radical (Fig. 2) (45). The addition of
purified ferredoxins causes a marked stimulation ofthe
reduction ofmetronidazole to its anionradical (45), sug-
gesting a role of a ferredoxin in this process. A stim-
ulatoryeffect offerredoxins onmetronidazole reduction
wasfirst demonstrated incrudeextractsofClostridium
acetobutylicum (49), C. pasteurianum (50), and T.foe-
tus (51) supplied with pyruvate as electron donor. This
stimulatory effect can also be observed in hydrogeno-
somal preparations from T.foetus or T. vaginalis sup-
plemented with the purified ferrodoxin from the same
organism (52-54). Since reduction ofnitroimidazoles by
ferredoxin-depleted hydrogenosomal extracts of
T.vaginalis is still possible (54), it has been suggested
A.
that reduction of these compounds in the presence of
ferredoxin is the sum oftwo processes, i.e., direct re-
duction by pyruvate:ferredoxin oxidoreductase and re-
duction mediated by ferredoxin. Accordingly, although
the reduction rate ofseveral nitroimidazoles tested de-
pended on the one-electron mid-point potential (E') of
the compound, the rate of additional reduction (stimu-
lated rate minus basal rate) of all compounds was in-
dependent ofthe E' ofthe compound (54).
It has been postulated that trichomonad ferredoxins
canbe the acceptors ofelectrons frompyruvate through
the pyruvate:ferredoxin oxidoreductase and that re-
duced ferredoxins can, then, reduce the nitroimidazoles
(20) [Eq. (7)].
Fd
Fd-
This reaction competes with the reaction catalyzed by
the hydrogenase [reaction (6)]. Accordingly, trichomon-
ads do not produce H2 in the presence ofmetronidazole
(55), and H2productionresumesafteralltheaddeddrug
is reduced (55,56).
It is interesting to note that the metronidazole anion
radical can also be observed in incubations of T.foetus
hydrogenosomal fraction and NADH, although no stim-
CH2-CHOH
4 CH.
4 N3
20 G
B.
_W~~~~~~~~~ 4
FIGURE 2. ESR spectra of T. foetus hydrogenosomes (A) in the presence and (B) absence of metronidazole: (A) The ESR spectrum of
metronidazole anionradicalobserved afterincubation of10mMmetronidazolewith 5mMpyruvate, 1 mM CoAand T.foetushydrogenosomal
fraction (1 mg/ml) in buffer (pH 7.4). (B) Identical with (A) but incubation without metronidazole. From Moreno et al. (45) with permission.
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ulation by ferredoxins is observed in this case (45).
These results imply that pyruvate:ferredoxin oxido-
reductase isnotthesole systemintrichomonadscapable
ofreducing metronidazole (45).
In contrast with the results obtained with metroni-
dazole, no stimulation of nitrofuran reduction is ob-
served on addition of ferredoxins to T. foetus hydro-
genosomes in the presence ofeitherpyruvate or NADH
as electron donor (45).
Accordingto the proposed redox cyclingofnitro com-
pounds [reaction (3)], aerobic incubations of T. foetus
hydrogenosomal fraction with metronidazole result in
the consumption of 02 and the generation of 02- and
H202 (45). The addition of purified ferredoxins also
causes a marked stimulation of metronidazole-induced
02 consumption by these preparations (45). A very high
concentration ofmetronidazole is necessary for the de-
tection of an increase in the 02 consumption and 02-
and H202 formation by the hydrogenosomal fraction. In
addition, metronidazole can not stimulate 02 consump-
tion in intact cells when used at low concentrations (less
than 6mM). Thus, redoxcyclingofmetronidazole under
aerobic conditions might be considered as a detoxifica-
tion reaction by inhibiting net reduction of the drug,
thereby inhibiting its uptake (56). The resulting low
steady state concentrations of02 and H202 are easily
detoxified by the superoxide dismutase and catalase
present in these parasites (57-59).
Recent experiments with T. vaginalis support the
role ofredox cycling ofmetronidazole as adetoxification
reaction (44). Thus, a resistant strain has been postu-
lated to have a greater rate of nitro anion radical dis-
appearance attr.buted to a higher intracellular 02 par-
tial pressure due to a deficiency in its 02-scavenging
systems (44).
In contrast with the results obtained with metroni-
dazole, lower concentrations of nitrofurans are neces-
sary for the detection of an increase in the 02 con-
sumption and 02- and H202 formation by the
hydrogenosomal fraction, and this process is not stim-
ulatedbyferredoxins (45). Inaddition, nitrofurans stim-
ulate 02 consumption in intact cells when used at low
concentrations (less than 6 mM) (45). These results im-
ply that oxygen-derived radicals can play a role in ni-
trofuran toxicity under aerobic conditions and can ex-
plain the efficacy of nitrofurans in topical treatment of
trichomonad infections of the vagina (60), where high
concentrations of the drugs can be achieved in not
strictly anaerobic conditions. In this regard, it is inter-
estingtonotethatlowconcentrations ofH202havebeen
shown to be toxic against T.foetus, and H202 has been
used for the treatment of T. foetus infection in bulls
(10).
The reduction of metronidazole and further air oxi-
dation of the anion radical explain the rather puzzling
observation, that, although the reduction-dependent
uptake ofmetronidazole (56) is markedly diminished by
air, it is not entirely suppressed (56). Thus, the lower
toxicity of metronidazole against trichomonads under
aerobic conditions (56) can be explained by this detox-
ification reaction, which inhibits the formation of the
unstable intermediate that interacts with DNA (61).
This interaction with DNA is believed to be the mech-
anism of toxicity (62). Although the nitro anion radical
is probably not the unstable intermediate which binds
to DNA (26), it must be an obligatory intermediate in
its formation. Whether one of the other two radicals
(hydronitroxide and amino cation radical) or a diamag-
neticproductofnitroreduction (nitroso, hydroxylamine,
amine) is involved in metronidazole toxicity remains to
be elucidated.
In conclusion, redox cycling of metronidazole under
aerobic conditions might be considered as a detoxifica-
tion reaction by inhibiting net reduction of the drug,
thereby inhibitingits uptake. The resultinglow steady-
state concentrations of62 are easily detoxified by the
superoxide dismutase presentintheseparasites. Onthe
other hand, redox cycling of nitrofurans or other com-
pounds with more positive reduction potential will re-
sult in formation ofhigh steady-state concentrations of
oxygen-derived metabolites that might be oftoxicolog-
ical significance.
Furthermetabolismofmetronidazoleintrichomonads
involves ring opening with formation of acetamide and
possible N-(2-hydroxyethyl)oxamic acid [Eq. (8)], al-
though only acetamide was identified in T. vaginalis
incubations (63). The amountofacetamideformedunder
anaerobic conditions appeared to be two- to fourfold
greater than that formed aerobically (63). However,
these products of metronidazole metabolism lack the
activity of the parent compound (20). The absence of
activity in the end products is regarded as strong evi-
dence that one or severalintermediates ofthereductive
process of the nitro group are responsible for the ob-
served cytotoxicity (20).
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Incubation of T. foetus with (14C)-metronidazole re-
sults in binding of the label to subcellular proteins and
possibly to other components such as DNA (56). Me-
tronidazole also inhibits the uptake of 14C-labeled thy-
mine and uridine in T. vaginalis (62). Thus, an inter-
action with DNA of the reactive metabolite or
metabolites of metronidazole and the subsequent inhi-
bition ofnucleic acids and protein synthesis is the most
widely held explanation for its toxic action on Tricho-
monas (20).
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Free-Radical Metabolites of
Metronidazole and Other
Nitroimidazoles in Animal Tissues
Besides their wide use in the treatment of bacterial
and parasitic disease (20,64,65), nitroimidazoles have
been used in cancer therapy, both as radiosensitizers
and as cytotoxic agents (66-68). Radiosensitization, hy-
poxic cell toxicity, and chronic aerobic toxicity correlate
with the electron affinity (redox potential) of the ni-
troimidazoles (68). This similarity suggests that redox
processes are involved in each phenomenon, but does
not necessarily indicate a common mechanism (68). One
ofthe major concerns in the clinical application ofthese
drugs is that they may be cytotoxic to the normal hy-
poxic tissues in the human body (nerve, skin, cartilage,
etc). For instance, side effects such as skin eruptions,
polyneuropathy, and psychic disturbances are usually
observed after prolonged treatment with nitroimida-
zoles (34).
Metronidazole and ronidazole are reduced by ratliver
microsomes to their nitro anion radicals, as indicated
by ESR spectroscopy (69). They also increase 02 con-
sumption and 02 formation by rat liver microsomes.
However, very high concentrations of nitroimidazoles
are necessary to demonstrate these effects (69). These
results imply that the effect of nitroimidazoles on 02
formation in mammalian tissues is small, hardly ex-
ceeding the basal levels. As occurs in trichomonads,
redox cycling of nitroimidazoles under aerobic condi-
tions might be considered as a detoxification reaction
by inhibiting net reduction of the drugs. Since mam-
malian tissues have a predominant aerobic metabolism,
this process is of significant protective value.
In addition to the microsomal enzyme components,
xanthine oxidase (70,71) is also capable ofcatalyzingthe
reduction of metronidazole and other nitroimidazoles.
N-(2-hydroxyethyl)oxamic acid and acetamide form in
this system when metronidazole is reduced (70). These
metabolites are also formed by intestinal flora and can
be detected in the urine when metronidazole is admin-
istered to to rats or humans (72-74). Together, N-(2-
hydroxyethyl)oxamic acid and acetamide account for all
the carbon and nitrogen atoms ofmetronidazole except
for the nitrogen atom in the nitro group.
However, most of the metabolites of metronidazole
excreted in urine contain the nitro group (75-77). The
main metabolites are the sulfo and glucuronic conju-
gates and the oxidation products ofmetronidazole: 1-(2-
hydroxyethyl-2-hydroxymethyl-5-nitroimidazole, 1-(2-
hydroxyethyl)-2-carboxyl-5-nitroimidazole, and 1-acetic
acid-2-methyl-5-nitroimidazole.
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Nevertheless, theabsence orlowcontentofreductive
metabolites in vivo does not imply that nitro reduction
to the anion radical has not occurred. Whole animal
studies which show no net formation of products may
be misleading in ascertaining the importance of free
radicalintermediates, becausefutilemetabolismischar-
acteristic of many classes of free radicals (26).
The mechanism of the neurotoxicity of nitroimida-
zoles is not completely understood. Based on results of
inhibition ofplant fatty acid synthesis by metronidazole
and several other nitroimidazoles, some authors (78)
have proposed this as a possible mechanism oftoxicity.
However, no experiments with mammalian systems
have been reported to date.
With regard to the mechanism of radio and chemo-
sensitization, most authors have preferred mechanisms
operating at the cellular level, including thiol depletion
and inhibition of DNA damage repair (79). However,
recent evidence has indicated that changes in pharma-
cokinetics, possibly through inhibition of drug-metab-
olizing enzymes in liver, may also be important for the
chemosensitization (80).
Finally, recent studies with ronidazole (81-86) have
shed light on the possible mechanism of toxicity of 5-
nitroimidazoles to animal tissues. Under different ex-
perimental conditions leading to enzymatic reduction of
this compound, reactive metabolites that bind cova-
lently to protein were produced (81-86). This covalent
binding was effectively prevented by reduced glutathi-
one and cysteine. The principal targets of protein al-
kylation were cysteine thiols (83). A ronidazole-cys-
teine adduct couldbeisolated (85) ininvitroincubations
ofratlivermicrosomes, suggestingthatthisadductmay
account for the observed binding of ronidazole to mi-
crosomal protein and for the presence of intractable
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drug residues in the tissues ofthe animals treated with
this compound.
Genotoxic Action of Nitroimidazoles
Nitroimidazoles interact with DNA (19,87-89) and
have mutagenic action in bacteria (12,90). Reports of
the nature of the target site of nitroimidazoles in the
DNA areconflicting. Some authors have shownthatthe
interaction of chemically reduced nitroimidazoles with
DNA is directly proportional tothe G + C content (61).
This was also confirmed by experiments in which guan-
ine was modified by chemically (91) or electrolytically
(87) reduced nitroimidazoles without affectingthe DNA
backbone. However, other investigators have shown
fragmentation of the DNA (single- and double-strand
breaks) by the activated nitroimidazoles and a prefer-
ential release ofthymidine phosphate after electrolytic
reduction of nitroimidazoles in the presence of DNA
(19,87,88,92).
Metronidazole and other5-nitroimidazoles are "direct
mutagens" in S. typhimurium TA 100 (i.e., they induce
mutations in this bacteria without the addition of ex-
ogenous "activating" systems such as rat liver S-9) (93-
99). Addition of rat liver S-9, however, enhances the
mutagenic activity ofmetronidazole, but onlyunder an-
aerobic conditions (96). A survey of 11 nitroimidazoles
showedthatonlythose compoundsthathave areducible
nitro group are active (93). The analysis of the muta-
genicity tests performed with different mutant strains
ofS. typhimurium (94-96) showed that error-prone re-
pair processes are involved in their mutagenic action.
Mutagenicity of metronidazole and other 5-nitroimi-
dazoles is probably the result ofmetabolic activation to
reduced forms, rather than to the unmetabolized com-
pounds per se. Experimental data from mutagenicity
assays of different nitroimidazoles support this conclu-
sion. Thus, nitroimidazoles are able to mutate S. ty-
phimurium TA 100, which has both oxygen-insensitive
and oxygen-sensitive nitroreductase activity, with or
without the addition ofrat liver S-9, under aerobic and
anaerobic conditions (96). However, TA 100-FRI, amu-
tant of TA 100 lacking oxygen-insensitive nitroreduc-
tase, is not aerobically mutable by nitroimidazoles in
the absence of the rat liver S-9 fraction (96,97). Since
this strain of bacteria retains oxygen-sensitive nitro-
reductase, it is mutable anaerobically with or without
the S-9 fraction of rat liver (96).
Mutagenic activity of nitroimidazoles has also been
detected inKlebsiellapneumoniae (12,90), Escherichia
coli (98), and yeast (99).
Recent work with several nitroimidazoles suggests
that ring opening ofpartially reduced compounds may
lead to biologically active agents. For example, metab-
olismofmetronidazole byintestinalbacteriayieldsacet-
amide, a compound known to be carcinogenic (71). In
addition, misonidazole, when reduced by xanthine oxi-
dase and xanthine, breaks downto glyoxal, whose reac-
tivity with proteins and nucleic acids is well known
(100).
Finally, with regard tothe carcinogenicity ofnitroim-
idazoles, the reports are conflicting and are reviewed
elsewhere (1,19).
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